Phase III study evaluating efficacy and safety of MK-6482 + lenvatinib versus cabozantinib for second- or third-line therapy in patients with advanced renal cell carcinoma (RCC) who progressed after prior anti-PD-1/L1 therapy.
Robert J. Motzer(Memorial Sloan Kettering Cancer Center), Daniel Yick Chin Heng(University of Calgary), Rodolfo F. Perini(Merck & Co., Inc., Rahway, NJ, USA (United States)), Yayan Zhang(Merck & Co., Inc., Rahway, NJ, USA (United States)), Yanfang Liu(Second Military Medical University)
Cited by 6
Related Papers
Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma
|New England Journal of Medicine|2018|4.6k
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
|Nature Genetics|2019|4.4k
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
|New England Journal of Medicine|2017|3.4k
First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study
|The Lancet Oncology|2017|1.3k
Kidney Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2022|645